Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought

Executive Summary

But elephant in the room –  the coming stream of readouts from Phase III PIONEER trials on oral semaglutide  in Type 2 diabetes – gets little mention at first-quarter update.

You may also be interested in...



Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.

Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal

Denmark's diabetes specialty company has linked up with a US biotech to evaluate a lysophosphatidic acid receptor antagonist in diabetic and chronic kidney disease.

Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel